ACAD NASDAQ
Acadia Pharmaceuticals Inc.
1W: -1.3%
1M: -1.8%
3M: -23.4%
YTD: -23.3%
1Y: -8.4%
3Y: -9.0%
5Y: +14.0%
$20.17
+0.43 (+2.18%)
Weekly Expected Move ±4.8%
$18
$19
$20
$21
$22
Credit Risk of going bust: lower than 86% of companies Debt: 2.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.04 (down 99.8%), Acadia Pharmaceuticals Inc. would be worth roughly what it owes.
Total debt $73.9M against a stock market value of $3.48B.
Distance to default 11.68 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $36.9M (short-term plus half of long-term), stock volatility 39.1%; Altman Z'' 3.47. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.04 (down 99.8%), Acadia Pharmaceuticals Inc. would be worth roughly what it owes.
Total debt $73.9M against a stock market value of $3.48B.
Distance to default 11.68 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $36.9M (short-term plus half of long-term), stock volatility 39.1%; Altman Z'' 3.47. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?
4 CNS Drug Stocks Worth Watching This World Mental Health Day
ACADIA Pharmaceuticals (NASDAQ:ACAD) Sets New 1-Year Low – Here’s What Happened
Acadia, Zydus patent litigation case looks resolved, says RBC
These ten healthcare stocks posted the biggest one-month losses
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041
What is HC Wainwright’s Forecast for ACAD FY2027 Earnings?
Traders Purchase Large Volume of Put Options on ACADIA Pharmaceuticals (NASDAQ:ACAD)
Acadia Pharmaceuticals drops 7%, continuing fall after drug trial results
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal
Acadia falls after mid-stage trial setback for Alzheimer’s psychosis therapy
Bank of America Corp DE Purchases New Position in ACADIA Pharmaceuticals Inc. $ACAD
Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?
Alyeska Investment Group L.P. Purchases Shares of 310,287 ACADIA Pharmaceuticals Inc. $ACAD
Canada Pension Plan Investment Board Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD
Connor Clark & Lunn Investment Management Ltd. Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD
Acadia Gets European Commission Nod for Daybu in Rett Syndrome
BlackRock Inc. Purchases Shares of 22,515,173 ACADIA Pharmaceuticals Inc. $ACAD
Emerald Investment Advisers LLC Acquires Shares of 131,752 ACADIA Pharmaceuticals Inc. $ACAD
Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last?
Empowered Funds LLC Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD
Assenagon Asset Management S.A. Sells 57,075 Shares of ACADIA Pharmaceuticals Inc. $ACAD
Bank of America Corp DE Acquires 332,325 Shares of ACADIA Pharmaceuticals Inc. $ACAD
Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript
ACADIA Pharmaceuticals (NASDAQ:ACAD) Reaches New 52-Week High – What’s Next?
Empowered Funds LLC Purchases Shares of 48,982 ACADIA Pharmaceuticals Inc. $ACAD
Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?
Can Acadia (ACAD) Run Higher on Rising Earnings Estimates?
3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations
ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales
Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates
Viatris Gears Up to Report Q2 Earnings: What's in the Cards?
ZTS Set to Report Q2 Earnings: Here's What Investors Should Expect
Outlook Therapeutics to Report Q3 Earnings: What's in the Cards?
Earnings Week Ahead: PLTR, AMD, PFE, DIS, SHOP, VTRS, CGC, MCD, ROKU, ABNB, and more
Avidity Partners Management LP Sells 93,933 Shares of ACADIA Pharmaceuticals Inc. $ACAD
HRMY or ACAD: Which Is the Better Value Stock Right Now?
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
The Zacks Analyst Blog Highlights CVS Health, Cardinal Health, Humana and ACADIA Pharmaceuticals
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
4 Medical Stocks With the Right Setup for Q2 Earnings Beats
Vertex Gears Up to Report Q2 Earnings: What Can Investors Expect?
Neurocrine Gears Up to Report Q2 Earnings: What's in the Cards?
Incyte Gears Up to Report Q2 Earnings: Is a Beat Around the Corner?
Wall Street Analysts Believe Acadia (ACAD) Could Rally 30.89%: Here's is How to Trade
ACADIA Pharmaceuticals Inc. $ACAD Shares Acquired by Bessemer Group Inc.
Acadia Gets FDA's Fast Track Tag for Alzheimer's Disease Candidate
Allspring Global Investments Holdings LLC Buys 296,042 Shares of ACADIA Pharmaceuticals Inc. $ACAD
An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?
Verastem (VSTM) Surges 6.3%: Is This an Indication of Further Gains?
RPRX or ACAD: Which Is the Better Value Stock Right Now?
ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome
Strength Seen in Acadia (ACAD): Can Its 6.8% Jump Turn into More Strength?
Why Acadia Pharmaceuticals Stock Is Soaring Today
Acadia rises as EU backs Rett syndrome therapy
Acadia (ACAD) Down 3.7% Since Last Earnings Report: Can It Rebound?
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh
MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
Acadia reaffirms 2026 total revenue guidance of $1.22B-$1.28B as remlifanserin Phase II ADP readout nears
Acadia (ACAD) Q1 2026 Earnings Transcript
Acadia Pharmaceuticals (ACAD) Lags Q1 Earnings and Revenue Estimates
Earnings Scheduled For May 6, 2026
Acadia Pharma GAAP EPS of $0.02 misses by $0.03, revenue of $268.06M misses by $12.21M
Here are the major earnings after the close Wednesday
ImmunityBio to Report Q1 Earnings: What's in the Cards?
IQVIA Set to Report Q1 Earnings: Here's What You Should Know
Guardian Pharmacy Services to Report Q1 Earnings: What's in the Cards?
CSLLY vs. ACAD: Which Stock Is the Better Value Option?
Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
Axecap Investments LLC Has $3.65 Million Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD
ACADIA Pharmaceuticals Inc. (ACAD) PT Trimmed Slightly as RBC Flags Seasonal Biotech Headwinds
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of “Moderate Buy” from Brokerages
Choreo LLC Purchases Shares of 23,186 ACADIA Pharmaceuticals Inc. $ACAD
CSLLY vs. ACAD: Which Stock Should Value Investors Buy Now?
Mark Schneyer Sells 2,709 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock
Will Acadia (ACAD) Beat Estimates Again in Its Next Earnings Report?
ACADIA Pharmaceuticals Inc. $ACAD Shares Bought by Allspring Global Investments Holdings LLC
Trump may impose tariffs on drugmakers who haven't signed MFN deals - reports
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of “Moderate Buy” from Brokerages
Why Is Acadia (ACAD) Down 12.9% Since Last Earnings Report?
This General Motors Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Hudson Bay Capital Management LP Sells 119,700 Shares of ACADIA Pharmaceuticals Inc. $ACAD
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech
Algert Global LLC Has $8.54 Million Stake in ACADIA Pharmaceuticals Inc. $ACAD
AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead?
ACADIA Pharmaceuticals Inc. $ACAD Shares Sold by First Trust Advisors LP
JAZZ or ACAD: Which Is the Better Value Stock Right Now?
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised)
ACADIA Pharmaceuticals Inc. $ACAD Stock Position Raised by Fisher Asset Management LLC
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Rating of “Moderate Buy” by Analysts
HC Wainwright Brokers Decrease Earnings Estimates for ACAD
HC Wainwright Issues Negative Outlook for ACAD Earnings
ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
Acadia outlines 2026 revenue target up to $1.28B while advancing DAYBUE STIX and NUPLAZID growth